Literature DB >> 27295268

GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study.

R Parody1, L López-Corral2, O Lopez-Godino2, C Martinez3, R Martino4, C Solano5, P Barba6, D Caballero2, I García-Cadenas4, J L Piñana5, F J Marquez-Malaver1, L Vazquez2, A Esquirol4, J C H Boluda5, F Sanchez-Guijo2, J A Pérez-Simon1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27295268     DOI： 10.1038/bmt.2016.163

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.

Authors:  Teresa Caballero-Velázquez; Luis Ignacio Sánchez-Abarca; Silvia Gutierrez-Cosio; Belén Blanco; Cristina Calderon; Carmen Herrero; Soraya Carrancio; Concepción Serrano; Consuelo del Cañizo; Jesús F San Miguel; José A Pérez-Simón
Journal:  Haematologica       Date:  2012-04-24       Impact factor: 9.941

2.  Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens.

Authors:  Dora E Corzo-León; Michael J Satlin; Rosemary Soave; Tsiporah B Shore; Audrey N Schuetz; Samantha E Jacobs; Thomas J Walsh
Journal:  Mycoses       Date:  2015-03-24       Impact factor: 4.377

3.  A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.

Authors:  Joseph Pidala; Jongphil Kim; Heather Jim; Mohamed A Kharfan-Dabaja; Taiga Nishihori; Hugo F Fernandez; Marcie Tomblyn; Lia Perez; Janelle Perkins; Mian Xu; William E Janssen; Anandaraman Veerapathran; Brian C Betts; Frederick L Locke; Ernesto Ayala; Teresa Field; Leonel Ochoa; Melissa Alsina; Claudio Anasetti
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

4.  Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.

Authors:  Corey Cutler; N Lynn Henry; Colm Magee; Shuli Li; Haesook T Kim; Edwin Alyea; Vincent Ho; Stephanie J Lee; Robert Soiffer; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2005-07       Impact factor: 5.742

5.  A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.

Authors:  Roberto Rodriguez; Ryotaro Nakamura; Joycelynne M Palmer; Pablo Parker; Sepideh Shayani; Auyaporn Nademanee; David Snyder; Vinod Pullarkat; Neil Kogut; Joseph Rosenthal; Eileen Smith; Chatchada Karanes; Margaret O'Donnell; Amrita Y Krishnan; David Senitzer; Stephen J Forman
Journal:  Blood       Date:  2009-11-19       Impact factor: 22.113

6.  The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.

Authors:  Jose Antonio Perez-Simón; Rodrigo Martino; Rocío Parody; Mónica Cabrero; Lucía Lopez-Corral; David Valcarcel; Carmen Martinez; Carlos Solano; Lourdes Vazquez; Francisco J Márquez-Malaver; Jordi Sierra; Dolores Caballero
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

7.  A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.

Authors:  Brian Kornblit; David G Maloney; Barry E Storer; Michael B Maris; Lars Vindeløv; Parameswaran Hari; Amelia A Langston; Michael A Pulsipher; Wolfgang A Bethge; Thomas R Chauncey; Thoralf Lange; Finn B Petersen; Kai Hübel; Ann E Woolfrey; Mary E D Flowers; Rainer Storb; Brenda M Sandmaier
Journal:  Haematologica       Date:  2014-08-01       Impact factor: 9.941

8.  Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.

Authors:  Jose A Pérez-Simón; Rodrigo Martino; Dolores Caballero; David Valcarcel; Noemi Rebollo; Rafael de la Cámara; Javier Pérez de Oteiza; Inmaculada Heras; Maria V Calvo; Jordi Sierra; Jesús F San Miguel
Journal:  Biol Blood Marrow Transplant       Date:  2008-06       Impact factor: 5.742

9.  Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.

Authors:  Izaskun Ceberio; Sean M Devlin; Craig Sauter; Juliet N Barker; Hugo Castro-Malaspina; Sergio Giralt; Doris M Ponce; Lauren Lechner; Molly A Maloy; Jenna D Goldberg; Miguel-Angel Perales
Journal:  Leuk Lymphoma       Date:  2014-08-06

10.  Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.

Authors:  Philippe Armand; Supriya Gannamaneni; Haesook T Kim; Corey S Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Ann S LaCasce; Eric D Jacobsen; David C Fisher; Jennifer R Brown; George P Canellos; Arnold S Freedman; Robert J Soiffer; Joseph H Antin
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544
View more
  1 in total

1.  A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice.

Authors:  Asim Saha; Sharon Hyzy; Tahirih Lamothe; Katelyn Hammond; Nicholas Clark; Leanne Lanieri; Prashant Bhattarai; Rahul Palchaudhuri; Geoffrey O Gillard; Jennifer Proctor; Megan J Riddle; Angela Panoskaltsis-Mortari; Margaret L MacMillan; John E Wagner; Hans-Peter Kiem; Lisa M Olson; Bruce R Blazar
Journal:  Blood       Date:  2022-03-17       Impact factor: 22.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.